Evidence map›Paper›PMID 31234811›Full record

ArticleBMC cancer2019

Master regulator analysis of paragangliomas carrying SDHx, VHL, or MAML3 genetic alterations.

John A Smestad, L James Maher

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

John A SmestadMayo Clinic Medical Scientist Training Program, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
L James MaherDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA. maher@mayo.edu.
Mayo Clinic · USMayo Clinic in Arizona · US

Funding

Medical Scientist Traning Program at Mayo ClinicT32GM065841 · NIGMS · MAYO CLINIC ROCHESTER · PI KAUFMANN, SCOTT H, SCHIMMENTI, LISA A · 2003 to 2022
$5.8M
Molecular Basis of Familial ParagangliomaR01CA166025 · NCI · MAYO CLINIC ROCHESTER · PI MAHER, LOUIS JAMES · 2013 to 2017
$1.5M
Understanding succinate-induced global transcriptional and epigenetic reprogramming and identifying unique vulnerabilities intrinsic to SDH-deficient cellsF30CA220660 · NCI · MAYO CLINIC ROCHESTER · PI SMESTAD, JOHN ANDREW · 2017 to 2020
$187k
NCI NIH HHS 1F30A220660NCI NIH HHS 4T32GM065841NCI NIH HHS 5RO1CA166025NCI NIH HHS F30 CA220660NCI NIH HHS R01 CA166025NIGMS NIH HHS T32 GM065841
6 · The paper itself

Abstract

backgroundSuccinate dehydrogenase (SDH) loss and mastermind-like 3 (MAML3) translocation are two clinically important genetic alterations that correlate with increased rates of metastasis in subtypes of human paraganglioma and pheochromocytoma (PPGL) neuroendocrine tumors. Although hypotheses propose that succinate accumulation after SDH loss poisons dioxygenases and activates pseudohypoxia and epigenomic hypermethylation, it remains unclear whether these mechanisms account for oncogenic transcriptional patterns. Additionally, MAML3 translocation has recently been identified as a genetic alteration in PPGL, but is poorly understood. We hypothesize that a key to understanding tumorigenesis driven by these genetic alterations is identification of the transcription factors responsible for the observed oncogenic transcriptional changes.

methodsWe leverage publicly-available human tumor gene expression profiling experiments (N = 179) to reconstruct a PPGL tumor-specific transcriptional network. We subsequently use the inferred transcriptional network to perform master regulator analyses nominating transcription factors predicted to control oncogenic transcription in specific PPGL molecular subtypes. Results are validated by analysis of an independent collection of PPGL tumor specimens (N = 188). We then perform a similar master regulator analysis in SDH-loss mouse embryonic fibroblasts (MEFs) to infer aspects of SDH loss master regulator response conserved across species and tissue types.

resultsA small number of master regulator transcription factors are predicted to drive the observed subtype-specific gene expression patterns in SDH loss and MAML3 translocation-positive PPGL. Interestingly, although EPAS1 perturbation is detectible in SDH-loss and VHL-loss tumors, it is by no means the most potent factor driving observed patterns of transcriptional dysregulation. Analysis of conserved SDH-loss master regulators in human tumors and MEFs implicated ZNF423, a known modulator of retinoic acid response in neuroblastoma. Subsequent functional analysis revealed a blunted cell death response to retinoic acid in SDH-loss MEFs and blunted differentiation response in SDH-inhibited SH-SY5Y neuroblastoma cells.

conclusionsThe unbiased analyses presented here nominate specific transcription factors that are likely drivers of oncogenic transcription in PPGL tumors. This information has the potential to be exploited for targeted therapy. Additionally, the observation that SDH loss or inhibition results in blunted retinoic acid response suggests a potential developmental etiology for this tumor subtype.

Indexed as

Adrenal Gland NeoplasmsAlgorithmsAnimalsCells, CulturedDatabases, GeneticDNA-Binding ProteinsFibroblastsHumansMembrane ProteinsMiceMutationPheochromocytomaSuccinate DehydrogenaseTrans-ActivatorsTranscription FactorsTranscriptomeDNA-Binding ProteinsEbfaz protein, mouseMAML3 protein, humanMembrane ProteinsSDHC protein, mouseSDHD protein, humanSuccinate DehydrogenaseTrans-ActivatorsTranscription FactorsTretinoinVHL protein, humanVon Hippel-Lindau Tumor Suppressor ProteinMastermind-like transcriptional coactivator 3ParagangliomaPheochromocytomaRetinoic acidSuccinate dehydrogenaseTranscriptional networkTranscription factorvon Hippel-Lindau

Identifiers

PMID31234811
PMCPMC6591808
OpenAlexW2952375091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.